Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia

NCT05859698 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT05859698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05859698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 4
Overall status
Completed
Start date
May 9, 2023
Completion date
December 27, 2024
Enrollment
59 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, major depressive disorder, schizoaffective disorder, schizophrenia, tardive dyskinesia